Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition

Marta Cuenca; Niels Van Nieuwenhuijzen; Laura M Moesbergen; Andries Bloem; Monique C Minnema; Victor Peperzak

doi:10.3324/haematol.2021.279517

Targeting B-cell maturation antigen increases sensitivity of multiple myeloma cells to MCL-1 inhibition

Haematologica. 2022 Apr 1;107(4):980-983. doi: 10.3324/haematol.2021.279517.

Authors

Marta Cuenca¹, Niels Van Nieuwenhuijzen², Laura M Moesbergen¹, Andries Bloem³, Monique C Minnema⁴, Victor Peperzak⁵

Affiliations

¹ Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht.
² Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands; Department of Hematology, University Medical Center Utrecht, Utrecht University, Utrecht.
³ Central Diagnostic Laboratory, University Medical Center Utrecht, Utrecht.
⁴ Department of Hematology, University Medical Center Utrecht, Utrecht University, Utrecht.
⁵ Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht. v.peperzak@umcutrecht.nl.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

B-Cell Maturation Antigen*
Cell Line, Tumor
Humans
Multiple Myeloma* / drug therapy
Myeloid Cell Leukemia Sequence 1 Protein / genetics
Proto-Oncogene Proteins c-bcl-2

Substances

B-Cell Maturation Antigen
Myeloid Cell Leukemia Sequence 1 Protein
Proto-Oncogene Proteins c-bcl-2

Grants and funding

Funding: this investigation was supported by a Bas Mulder Award to VP from the Dutch Cancer Foundation (KWF)/Alped’HuZes foundation (award no. UU 2015-7663) and a project grant to VP from the Dutch Cancer Foundation (KWF)/Alped’HuZes foundation (grant no. 11108). MC was supported in part by a postdoctoral grant from the Ramón Areces Foundation.